Amylyx Pharmaceuticals, Inc.
$13.20
-0.68%Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -8.6).
Valuation inputs: P/E -8.6, earnings yield N/A, momentum -0.7%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -47.4%, ROIC -49.3%).
Profitability stack: net margin 0.0%, ROE -47.4%, ROIC -49.3%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +8.2%, momentum -0.7%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Amylyx Pharmaceuticals, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Amylyx Pharmaceuticals, Inc. Fair Value Envelope
Amylyx Pharmaceuticals, Inc. Profit Bridge
Profitability Analysis
Amylyx Pharmaceuticals, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Amylyx Pharmaceuticals, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Amylyx Pharmaceuticals, Inc. Street Expectations Map
Wall Street analysts project that AMLX stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 24.50, with estimates ranging from a low of 21.00 to a high of 28.00.
The consensus 1-year price target stands at 24.50, with estimates ranging from a low of 21.00 to a high of 28.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Amylyx Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have purchased $152K and sold $6.25M worth of AMLX shares, resulting in $6.10M of net selling activity.
3 Months
3.8K
51.34K
0
0.00
+51K
+$51K
3-6 Months
8.1K
100.84K
416.3K
5.73M
-5.6M
-$5.63M
6-9 Months
0
0.00
36.4K
522.37K
-522K
-$522K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Firestone Karen
Director
$152K
Top Sellers
Klee Justin B.
Director, Officer: Co-Chief Executive Officer
$3.04M
Cohen Joshua B
Director, Officer: Co-Chief Executive Officer
$2.62M
Frates James M
Officer: Chief Financial Officer
$204K
Mazzariello Gina
Officer: Chief Legal Officer
$198K
Bedrosian Camille L
Officer: Chief Medical Officer
$189K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $6.10M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
No Dividend Yield Data
AMLX has not reported any dividend yield values in the available annual periods.
amlx Dividend History
Learning Layer
Related Guides
Build conviction on AMLX by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.